DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/29db13/competitor_analysi) has announced the addition of La Merie's "Competitor Analysis: c-MET/HGF Inhibitors 2011" report to their comprehensive offering of the latest medical research publications.
This detailed intelligence report provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Purchase of the downloadable pdf report includes 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail, allowing editing of the project data to print or export an individual report.
The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. c-MET/HGF has thus evolved as an attractive target for the pharmaceutical industry.
The report includes a compilation of currently active projects in research and development of c-Met/HGF inhibitors. In addition, the report lists company-specific R&D pipelines of c-Met/HGF inhibitors in R&D. Competitor projects are listed in a tabular format providing information on: drug codes, target/mechanism of action, class of compound, company, product category, indication, R&D Stage, and additional comments with a hyperlink leading to the source of information.
- Abxign 21 Amgen
- ArQule 23 Astex Therapeutics
- AVEO Pharmaceutical 26 Bristol-Myers Squibb (BMS)
- Chroma Therapeutics 28 Daiichi Sankyo
- Deciphera Pharmaceuticals 29 Eisai
- Eli Lilly
- GlaxoSmithKline (GSK)
- Hutchison MediPharma Limited
- Johnson & Johnson
- Kringle Pharmaceuticals
- Kyowa Hakko Kirin
- Merck & Co
- Merck Serono
- ProMetic BioTherapeutics Inc
- Taiho pharmaceutical co
- Takeda Pharmaceutical Co.
- Tiger Pharmatech
For more information visit http://www.researchandmarkets.com/research/29db13/competitor_analysi